

REQUEST FOR CONTINUED EXAMINATION (RCE) TRANSMITTAL Address to: Mail Stop RCE Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450	Application Number	09/814,601
	Filing Date	March 23, 2001
	First Named Inventor	James T. Lynn et al.
	Group Art Unit	2137
	Examiner Name	Z. A. Davis
	Attorney Docket Number	GE04347

 RECEIVED
 CENTRAL FAX CENTER

SEP 19 2005

This is a Request for Continued Examination (RCE) under 37 C.F.R. § 1.114 of the above-identified application. Request for Continued Examination (RCE) practice under 37 CFR 1.114 does not apply to any utility or plant application filed prior to June 8, 1995, or to any design application. See Instruction Sheet for RCEs (not to be submitted to the USPTO).

1. Submission required under 37 C.F.R. 1.114 Note: if the RCE is proper, any previously filed unentered amendments and amendments enclosed with the RCE will be entered in the order in which they were filed unless applicant instructs otherwise. If applicant does not wish to have any previously filed unentered amendment(s) entered, applicant must request non-entry of such amendment(s).

a. ☐ Previously submitted. If a final Office Action is outstanding, any amendments filed after the final Office

Action may be considered as a submission even if this box is not checked.

i. ☐ Consider the arguments in the Appeal Brief or Reply Brief previously filed on _____.

ii. ☐ Other _____

b. ☒ Enclosed

i. ☒ Amendment/Reply

ii. ☐ Affidavit(s)/Declaration(s)

iii. ☐ Information Disclosure Statement (IDS)

iv. ☐ Other _____

2. ☐ Miscellaneous

a. ☐ Suspension of Action on the above-identified application is requested under 37 CFR 1.103(c) for a period of _____ months. (Period of suspension shall not exceed 3 months; Fee under 37 CFR 1.117(l) required.)

b. ☐ Other _____

3. ☒ Fees The RCE fee under 37 C.F.R. 1.117 (e) is required by 37 C.F.R. 1.114 when the RCE is filed.

a. ☒ The Director is hereby authorized to charge the following fees, or credit any overpayments, to Deposit Account No. 502117.

i. ☒ \$790.00 RCE fee required under 37 C.F.R. 1.17(e)

ii. ☒ \$ 450.00 Two (2) Month Extension of time fee (37 C.F.R. 1.136 and 1.17)

iii. ☐ Other _____

Total: \$ 1,240.00

b. ☐ Check in the amount of \$ _____ enclosed..

c. ☐ Payment by credit card (Form PTO-2038 enclosed)

SIGNATURE OF APPLICANT, ATTORNEY OR AGENT REQUIRED

Name (Printed/Type)

Larry T. Cullen

Reg. No.

44,489

Signature

Larry T. Cullen

Date

9/19/05

CERTIFICATE OF MAILING OR TRANSMISSION

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Mail Stop RCE, Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 or facsimile transmitted to the U. S. Patent and Trademark Office on: 9/19/05

Name

Larry T. Cullen

Signature

Larry T. Cullen

09/21/2005 SSESHE1 00000081 502117 09814601

01 FC:1801 790.00 DA

**MOTOROLA**

Broadband Communications Sector

Law Department
101 Tournament Drive
Horsham, PA 19044**RECEIVED
CENTRAL FAX CENTER****SEP 19 2005****FAX**Date: September 19, 2005Number of pages including cover sheet: 9**To: United States Patent &
Trademark Office**

Phone:

Fax:- 571-273-8300

cc:

From: Larry T. Cullen**Sr. Intellectual Property
Counsel**Phone: 215-323-1797Fax: 215-323-1300

The information contained in this facsimile message is legally privileged and confidential information intended only for the use of the addressee(s) named above. If the reader of this message is not the intended recipient, you are hereby notified that any dissemination, distribution or copy of this telecopy is strictly prohibited. If you have received this telecopy in error, please notify us immediately by telephone (800) 523-8878 and return the original to the sender at the address above by U.S. Mail. We will reimburse any costs you incur in notifying us and returning the message to us. Thank you.

REMARKS: ☐ Urgent ☐ For your review ☐ Reply ASAP ☐ Please comment

Application No: 09/814,601

Examiner: Z.A. Davis

Art Unit: 2137

Docket: GE04347

**RECEIVED
OIPE/IAP****SEP 21 2005**